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Suppression of estrogen biosynthesis by aromatase inhibition is an effective approach for the treatment of
hormone sensitive breast cancer. Third generation non-steroid aromatase inhibitors have shown important
benefits in recent clinical trials with postmenopausal women. In this study we have developed a new ligand-
based strategy combining important pharmacophoric and structural features according to the postulated
aromatase binding mode, useful for the virtual screening of new potent non-steroid inhibitors. A small
subset of promising drug candidates was identified from the large NCI database, and their antiaromatase
activity was assessed on an in vitro biochemical assay with aromatase extracted from human term placenta.
New potent aromatase inhibitors were discovered to be active in the low nanomolar range, and a common
binding mode was proposed. These results confirm the potential of our methodology for a fast in silico
high-throughput screening of potent non-steroid aromatase inhibitors.
Introduction
Aromatase, a member of the cytochrome P450 superfamily
that catalyzes the final and key step of C19 steroids conversion
to estrogens,1 is a very attractive target for the endocrine
treatment of breast cancer.2 In this sense, attention has been
focused on the discovery of aromatase inhibitors able to decrease
the circulating levels of estrogens and therefore control the
progression of hormone sensitive breast cancer.3
P450 enzymes are monooxygenases that catalyze a large
number of reactions involved in drug metabolism and synthesis
of steroids and lipids.4 There are more than 7700 different P450
sequences identified to date.5 The design of potent and selective
inhibitors to a single member of this superfamily represents a
very challenging task. In spite of these hurdles, selective
aromatase inhibitors have been discovered, such as fadrozole
and formestane, a second generation of aromatase inhibitors,
or exemestane, letrozole, anastrozole, and vorozole, a third
generation of aromatase inhibitors.6 On the basis of their
inhibition mechanisms, these molecules are divided into two
classes: (1) irreversible steroid inactivators such as formestane
or exemestane that bind covalently to the enzyme and (2) non-
steroid inhibitors such as letrozole or anastrozole that act as
reversible competitive inhibitors.
Improvements in the rational design of new aromatase
inhibitors could be obtained once a high resolution 3D structure
of the enzyme becomes available. However, to date, no X-ray
structure of aromatase has been published in the Protein Data
Bank, despite recent progress in the 3D determination of
mammalian and human cytochrome P450 enzymes.7-10 On this
basis, several homology models for aromatase11-13 have been
built and proved to be valuable in understanding the binding
determinants of several classes of inhibitors.14-16 The low
sequence identity between members of different P450 families
may, however, limit their potential in structure-based virtual
screenings.
An alternative strategy for the rational design of new
aromatase inhibitors relies on ligand-based virtual screening that
can be developed on the basis of the vast information on strong
aromatase inhibitors published in the literature. Pharmacophore-
based approaches have been used for both steroid and non-
steroid aromatase inhibitors, highlighting important physico-
chemical features and guiding the design of new potent
compounds.17-20 However, to date, only a few attempts to
perform virtual screening based on such models have been
performed. Langer and co-workers, for instance, have carried
out a mixed qualitative and quantitative approach for non-steroid
aromatase inhibitors, using the HipHop and HypoRefine algo-
rithms of the Catalyst software.21 The final pharmacophore
model proposed by this group consisted of one aromatic ring
feature, one hydrophobic group, two hydrogen bond acceptors,
and one excluded volume sphere. Two possible antiaromatase
candidates were identified on the basis of this approach, one of
the compounds being able to decrease in 68% the activity of
the enzyme at 36 µM and the other in 15% at the same
concentration.
In this study we have used known non-steroid aromatase
inhibitors to derive and validate a new pharmacophore model
for fast in silico screening of antiaromatase compounds. The
model combined information about the common pharmacophore
features of azole non-steroid inhibitors, information about their
binding to the aromatase active site, steric restrictions and a
“druglikeness” filter. The large NCIa compound database was
screened using this methodology, and new potent aromatase
inhibitors were identified. The new compounds have in vitro
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activity comparable to that of second and third generation
antiaromatase agents. Furthermore, the most active molecules
were docked on the active site of an aromatase homology
model12 and these results were compared with the pharmacoph-
ore model.
Results and Discussion
3D-Pharmacophore Generation. Several non-steroid aro-
matase inhibitors have been used for the treatment of breast
cancer in postmenopausal women, with clinical efficacy.2
Having progressed through a preclinical development and
clinical trials, these compounds are expected to include informa-
tion about strong antiaromatase potency and selectivity. In this
study, we have built a training set with low energy conforma-
tions of second and third generation aromatase inhibitors,
namely, anastrozole, letrozole, fadrozole, and vorozole (Figure
1) and used these molecules to generate a common-features
pharmacophore model with the HipHop22 algorithm of the
Catalyst software.23 Briefly, the program evaluates chemical
features common to a set of active compounds and generates
hypotheses for their activity. These hypotheses are spatial
dispositions of pharmacophoric points providing the compounds’
relative alignment in the binding site of the enzyme. Each point
accounts for an important chemical feature such as hydrogen
bond donors/acceptors, hydrophobic groups, negative/positive
ionizable groups, and aromatic groups. Basic physicochemical
features of known antiaromatase compounds include a high
degree of hydrophobicity and the potential to establish hydrogen
bonds as acceptors. These properties are related to the highly
apolar binding pocket of the enzyme which is expected to have
at least one hydrogen bond donor residue.24 Therefore, hydro-
phobic (HYD) and hydrogen bond acceptor (HBA) pharma-
cophoric features were used in this study. The program found
six possible alignment solutions displaying three or four
pharmacophoric points. The first two top ranked solutions,
HYP1 (rank ) 31.9) and HYP2 (rank ) 29.8), had four features,
two hydrophobic groups, and two hydrogen bond acceptors.
Analysis of the training set molecules aligned to these hypoth-
eses revealed overlapping imidazole and triazole groups in
HYP2 but not in HYP1, with one nitrogen atom acting as
hydrogen bond acceptor (HBA1, Figure 2). This feature of
HYP2 reflects the binding mechanism found for this type of
molecule, which entails binding through heterocyclic aromatic
coordination to the heme iron of the P450 active site.6 Therefore,
HYP2 was chosen for the subsequent steps. The second
hydrogen bond acceptor feature (HBA2, Figure 2) matches either
a cyano group (anastrozole, letrozole, and fadrozole) or the N2
atom of a methylbenzotriazole (vorozole), and the hydrophobic
features superimpose with phenyl rings of all the molecules
(HYD1, Figure 2), the methyl of the anastrozole, or the
piperidine moiety of the fadrozole (HYD2, Figure 2).
Pharmacophore models with a small number of points tend
to be unspecific and return a large number of hits when used to
screen large databases. In particular, hydrophobic and hydrogen
bond acceptor features match a large number of chemical
groups, increasing the number of false positives. Therefore, in
an attempt to increase the specificity of HYP2, the HBA1 feature
was substituted with new fragment/function pharmacophoric
features: the C5-N-HBA and the C6-N-HBA features (Figure
3). C5-N-HBA matches hydrogen bond acceptors only if present
in certain types of five-membered nitrogen-containing hetero-
cyclic rings (imidazole, 1,2,4-triazole, 1,2,3-triazole, and tetra-
zole), whereas C6-N-HBA matches acceptors from six-
membered nitrogen-containing heterocyclic rings (pyridine,
pyridazine, pyrimidine, and pyrazine).
Cytochrome P450 enzymes have an inner binding pocket with
well defined volume accessible from the outside by several
channels.25 Therefore, besides the physicochemical properties
of the inhibitor, molecular shape is expected to be extremely
important to the access and fit within the active site of the
aromatase. Most aromatase inhibitors used to build the common-
features model have a similar shape that is expected to be
complementary to the volume of the aromatase active site. The
shape of letrozole, a quite rigid third generation inhibitor with
high degree of symmetry, was therefore converted into a set of
inclusion volumes and combined with the pharmacophoric query
(HYP2-HBA-Shape).
Therefore, the final pharmacophore model combined phar-
macophoric information (two hydrogen bond acceptors and two
hydrophobic groups) with fragment information (nitrogen-
containing aromatic heterocycles) and steric restrictions. All
aromatase inhibitors used on the training set matched the final
hypothesis with best fit values ranging from 2.98 to the
maximum value of 4.00 (letrozole ) 4.00, vorozole ) 3.46,
anastrozole ) 3.40, and fadrozole ) 2.98).
Model Validation. To validate the new pharmacophore
model, a test set with 82 non-steroid aromatase inhibitors
collected from the literature was built.17,26-31 Each molecule
contained a five- or six-membered aromatic heterocyclic ring
able to coordinate with the aromatase heme iron. The initial
pharmacophore model (HYP2) returned 58 molecules (71% of
the database, Table 1). The pharmacophore modified to match
Figure 1. Training set of azole non-steroid aromatase inhibitors used
for the common-features (HipHop) pharmacophore model generation.
Figure 2. Common-features (Catalyst/HipHop) pharmacophore model
of azole non-steroid aromatase inhibitors. The HYP2 pharmacophoric
query had four features: two hydrogen bond acceptors (HBA1 and
HBA2, green) and two hydrophobic groups (HYD1 and HYD2, cyan).
The training set aromatase inhibitors (anastrozole, red; letrozole, yellow;
fadrozole, green; vorozole, blue) are represented as the best fit alignment
to the model.
144 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 1 NeVes et al.
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acceptors from five- or six-membered nitrogen-containing
heterocyclic rings (HYP2-HBA) returned 40 molecules (49%
of the database). By use of the inclusion volumes (HYP2-HBA-
Shape), 26 molecules were retrieved (35% of the database).
Furthermore, the final subset was enriched with the most potent
aromatase inhibitors. These results demonstrate that the HYP2-
HBA-Shape pharmacophore model is able to identify not only
inhibitors from the training set but also potent non-steroid
aromatase inhibitors with different structures.
NCI Database Virtual Screening. One initial virtual screen-
ing (VS) run performed on the NCI database,32 a large library
with more than 290 000 molecules, with HYP2 returned more
than 90 000 molecules (Table 1). As expected, the reduced
number of pharmacophoric points failed to filter a large database
for aromatase inhibitors. The modified pharmacophore query
(HYP2-HBA) returned 676 hits, less than 0.3% of the total
number of molecules, and with the final hypothesis (HYP2-
HBA-Shape) 89 molecules were found, 0.03% of the total
number of molecules. Therefore, three different levels of filtering
were able to reduce a large database with thousands of molecules
to a small subset of promising antiaromatase candidates.
Calculations took about 6 min (HYP2), 24 s (HYP2-HBA), and
50 s (HYP2-HBA-Shape) to be completed on an Intel Pentium
D 3.4 GHz processor.
Postprocessing Filtering and Inspection of Molecular
Properties. The 89 hits derived from the NCI database were
superimposed with the HYP2-HBA-Shape pharmacophore query
and visually inspected. Furthermore, a Lipinski rule of five
filter33 was applied using the Instant JChem software.34 The
maximum number of rotatable bonds was set to 7 per molecule,
and the maximum polar surface area (PSA) was set to 150.
Furthermore, compounds with ester groups were avoided
because of possible in vivo hydrolysis. Twenty-nine molecules
were selected from the VS hits, 15 of these being available to
biological evaluation from the NCI open chemical repository
collection (Figure 4).
Four different types of nitrogen-containing aromatic hetero-
cycles were retrieved as hits, namely, imidazoles (compounds
1-6), one triazole (compound 7), pyridines (compounds 8-13),
and pyridazines (compounds 14 and 15). These nitrogen-
containing heterocycles are linked to several types of hydro-
phobic molecular scaffolds such as diphenylmethane (2, 3, 4,
and 14), arylbenzylsulfane (1), diphenylimidazole (13), pyridi-
nylbenzoimidazole (12), phenylpyridine (8), benzyl-1H-indol
(5), acridine (9), benzo/methylfuran (7), and quinoline (6) or
in other cases extended with another phenyl ring, such as in
two isoquinolines (10 and 11) and in one phthalazine (15). As
hydrogen bond acceptors, methoxy groups (1, 7, 9, and 14),
nitro groups (5, 11, 12, and 15), dioxol groups (2, 3, and 4),
hydroxyl groups (10 and 13), imidazole (6), and pyridine (8)
were found.
Before biochemical evaluation, these hits were inspected on
a large electronic collection of organic chemistry (CrossFire
Beilstein) using the MDL CrossFire Commander.35 Additional
searches were performed using the PubChem compound data-
base,36 a publicly available source of chemical and biological
Figure 3. C5-N-HBA and C6-N-HBA fragment/function pharmacophore features. Imidazole, 1,2,4-triazole, 1,2,3-triazole, and tetrazole rings were
combined into a single fragment feature using the centroids of the five membered ring moieties. Pyridine, pyridazine, pyrimidine, and pyrazine
rings were combined into another fragment feature using the centroids of the six membered ring moieties. Anchoring points to the rest of the
molecule are represented with doted lines. The nitrogen atom distal to these points defined a hydrogen bond acceptor and the projected point, the
position in space from which the participating hydrogen will extend. These two positions are connected by a vector that indicates the direction from
the heavy atom to the projected point of the hydrogen bond (C, black; N, blue; H, white).
Table 1. Screening Results of the Literature Database17,26-31 (Model
Validation) and NCI Database (Virtual Screening)
hypothesis literature database hits NCI database hits
HYP2 58 91050
HYP2-HBAa 40 676
HYP2-HBA-Shapeb 26 89
postprocessing filteringc 26 76
visual inspection 29
a HYP2 modified to match acceptors from five- or six-membered
nitrogen-containing heterocycles. b Letrozole was converted into a shape
query. The minimum similarity tolerance was set to 0.48. c Filters applied:
Lipinski rule of five, rotatable bonds e 7, PSA < 150.
VS of Non-Steroid Aromatase Inhibitors Journal of Medicinal Chemistry, 2009, Vol. 52, No. 1 145
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information for small molecules, including results from NCI
anticancer drug screenings. Of utmost importance was the
finding that none of them had been previously tested as
aromatase inhibitor.
Biochemical Evaluation. The VS hits were experimentally
evaluated for the ability to inhibit aromatase. Enzyme inhibition
was studied in vitro in an enzymatic assay according to Siiteri
and Thompson37 using human placental microsomes as the
source of aromatase.38 The molecules were initially screened
at 1 µM, followed by a full concentration-response study,
allowing the determination of the IC50 value (Table 2). Letrozole,
a third generation aromatase inhibitor, was used in the same
assay conditions as a reference compound.2
Interestingly, all molecules in the study were able to inhibit
the enzyme aromatase with IC50 potencies ranging from mi-
cromolar to the low nanomolar range. Compound 3 (IC50 )
5.3 nM) presented a better activity than letrozole (IC50 ) 6.1
nM), whereas compounds 1 (IC50 ) 25.0 nM), 2 (IC50 ) 24.9
nM), 4 (IC50 ) 55.0 nM), 9 (IC50 ) 76.0 nM), and 13 (IC50 )
47.7 nM) had better potency than formestane, a second
generation aromatase inhibitor previously studied in our group
in the same assay conditions (IC50 ) 92 nM).39
Kinetic analysis of the enzyme in the presence of the most
potent inhibitors was also performed (Table 2), and Lineweaver-
Burk plots were recorded. For all of them a mechanism of
competitive inhibition was found and the Ki values indicate that
they have a greater affinity to the active site of the enzyme than
the natural substrate androstenedione. Control experiments in
the absence of the inhibitors in the study allowed the determi-
nation of kinetic constants, Michaelis-Menten constant (Km )
92.3 nM), and maximum velocity of catalysis (Vmax ) 160.9
(pmol of substrate/min)/(mg of protein)).
Docking to the Active Site of an Aromatase Homology
Model. The most active compounds (1-6, 9, and 13) were
docked with the GOLD docking software40 on the active site
of an aromatase homology model built by Favia et al.12 based
on the structure of CYP2C9.9 The distance between the
coordinating nitrogen and the heme iron was constrained to a
value between 1.9 and 2.5 Å in order to reproduce the binding
mode found for non-steroid aromatase inhibitors.41 This distance
range was chosen on the basis of the analysis of P450 enzymes
found in the PDB database with imidazole and pyridine ligands
Figure 4. Selected NCI database hits.
Table 2. Aromatase Inhibitory Activity of the Selected NCI Database
Hits and Letrozole
compd NCI code IC50 (nM)a Ki (nM)a,b
1 NSC289311 25.0 ( 0.2 6.5 ( 0.1
2 NSC368272 24.9 ( 0.2 5.6 ( 0.1
3 NSC368280 5.3 ( 0.02 1.9 ( 0.03
4 NSC369087 55.0 ( 0.7 13.1 ( 0.2
5 NSC625409 190.3 ( 2.1 52.7 ( 0.8
6 NSC666292 96.0 ( 1.3 33.4 ( 0.4
7 NSC356483 3.1 × 103 ( 0.03 × 103
8 NSC598 46.7 × 103 ( 1.8 × 103
9 NSC12999 76.0 ( 1.0 25.5 ( 0.3
10 NSC131735 29.8 × 103 ( 0.7 × 103
11 NSC131736 1.4 × 103 ( 0.01 × 103
12 NSC356781 2.1 × 103 ( 0.02 × 103
13 NSC683634 47.7 ( 0.5 15.1 ( 0.3
14 NSC75308 5.6 × 103 ( 0.1 × 103
15 NSC226644 37.6 × 103 ( 0.8 × 103
letrozole 6.1 ( 0.1 2.2 ( 0.03
a Results shown are the mean ( SEM of three independent experiments.
b All compounds with reported Ki values were competitive inhibitors.
146 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 1 NeVes et al.
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complexed with the heme group.42-44 The GOLDScore fitness
function was used to rank the binding modes to the enzyme.
This scoring function is the negative of the sum of five energy
terms, i.e., protein-ligand hydrogen bond energy, protein-ligand
van der Waals energy, ligand internal van der Waals energy,
ligand torsional strain energy, and an additional constraint
scoring contribution.
Analysis of the docking results revealed that all the molecules
in the study fit well within the binding site cavity, with fitness
scores ranging from 53 to 68. With the exception of compounds
1 and 6, the top ranked poses of all molecules have a hydrogen
bond between an acceptor group and Ser 478. Slightly lower
scored binding modes of compound 1 (62 versus 67, pose ranked
number 12) and compound 6 (56 versus 57, pose ranked number
2) showed the same hydrogen bond interaction (Figure 5). These
results are in agreement with previous mutagenesis and docking
studies pointing out Ser 478 as a key residue to the catalysis
mechanism of the enzyme and binding of some non-steroid
aromatase inhibitors.12,15,45 Compounds 2, 3, and 4 share the
same binding mode, with another hydrogen bond between the
hydroxyl group and Thr 310. This extra anchoring point might
explain the strongest antiaromatase activity found for compound
3. More detailed analysis of the docking mode of compounds
1, 2, and 9 (Figure 5) revealed a very close superimposition of
hydrophobic and hydrogen bond acceptor pharmacophoric points
similar to the pharmacophore model used for the VS, HYP2
(Figure 2). The HYD1 area is defined by three phenyl rings
docked on an apolar region of the aromatase binding cavity,
defined by hydrophobic residues Val 313 and Leu 477. The
HYD2 area has either phenyl rings or a benzylsulfanyl group
fitting a small hydrophobic pocket due to Pro 368 and Val 370.
Letrozole, the reference compound used in this study, fits
into the binding pocket of the enzyme in a similar way to the
other compounds. Good superimposition is observed between
the hydrophobic and nitrogen-containing moieties of these
molecules.
Furthermore, the docking poses of compounds 1-6, 9, and
13 were loaded into Catalyst and rigidly fitted into the
pharmacophore model. With the exception of compound 5, all
the other docked conformations correctly fitted four groups into
the pharmacophore model. The average fit value was 2.45.
These results validate our pharmacophore model as a screen-
ing methodology for potent non-steroid aromatase inhibitors.
Conclusions
In this study, a new virtual screening strategy for potent non-
steroid aromatase inhibitors was proposed. The screening was
based on the common features of a training set of second and
third generation aromatase inhibitors (fadrozole, anastrozole,
letrozole, and vorozole), combined with heme coordinating
fragments (five- or six-membered nitrogen-containing aromatic
heterocycles), inclusion volumes, and several “druglikeness”
filters. The model was first validated theoretically on a literature
database of known aromatase inhibitors and used subsequently
to screen the NCI database, a large library of molecules focused
on research for new antitumor and AIDS antiviral agents. A
very small number of the NCI compounds (0.03%) was
identified as interesting antiaromatase candidates. Finally, the
model was validated experimentally by testing the most promis-
ing VS hits in an in vitro biochemical assay. New potent
aromatase inhibitors with similar or better in vitro potency than
the reference molecules were identified.
All tested compounds were able to inhibit the aromatase with
IC50 potencies ranging from micromolar to the low nanomolar
range. These results demonstrate that our VS strategy was very
effective at filtering this large compound database with no false
positives. Furthermore, several compounds had antiaromatase
activities between second and third generation aromatase
inhibitors (1, 2, 4, 9, and 13), and one of them (compound 3)
was stronger than the third generation reference. Kinetic studies
confirmed a competitive inhibition mechanism. These molecules
are therefore interesting targets for lead optimization and
ADMET studies.
Although to the best of our knowledge these compounds had
never been tested as aromatase inhibitors, molecules with the
diphenylmethylimidazole or the 3-((1H-imidazol-1-yl)methyl)-
1-benzyl-1H-indole motifs have already been reported as potent
aromatase inhibitors with IC50 values in the nanomolar range.46-48
Furthermore, compound 12 was tested previously for antimi-
crobial and antifungal properties with no activity on the assay
conditions,49 and compound 5 derivatives had antifungal activity
only when tested at micromolar concentrations.50 These results
indicate that such compounds, used at very low nanomolar
concentrations, might be selective for the aromatase enzyme.
However, additional studies must be performed in order to
confirm this hypothesis. Other interesting pharmacological
activities have also been identified for some of these molecules
and reported in the literature; for example, 9-anilinoacridines
related to compound 9 have potential antitumor activity due to
their DNA binding properties.51 Large scale screenings using
the NCI open chemical repository collection on the basis of
the NCI anticancer drug discovery program identified potential
new activities for compounds 1 and 6. Compound 1 was active
in vivo using a model for colon carcinoma in mice. Compound
6 was another interesting compound identified. It was found to
inhibit the growth of a human leukemia cell line.
Figure 5. Docked poses of compounds 1 (magenta), 2 (cyan), and 9
(yellow) into the binding site of an aromatase homology model.12
Dashed lines are drawn between Thr 310 and the hydroxy group of
compound 2 (distance ) 2.05 Å) and between Ser 478 and methoxy
groups of compounds 1 (distance ) 2.85 Å) and 9 (distance ) 2.61
Å), and a dioxol group of compound 2 (distance ) 2.42 Å). This figure
was reproduced using Pymol.55
VS of Non-Steroid Aromatase Inhibitors Journal of Medicinal Chemistry, 2009, Vol. 52, No. 1 147
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Docking of the most potent compounds into the active site
of a homology model of the aromatase12 led to a common
binding mode that is in good agreement with the common
features in the pharmacophore model. Besides the essential
HBA1 feature involved in coordination with the heme iron,
establishment of an additional hydrogen bond with Ser 478
appears to be important, therefore justifying the presence of the
HBA2 feature. Several apolar active site residues explain the
hydrophobic nature of the new aromatase inhibitors (HYD1 and
HYD2), and Thr 310, involved in an additional hydrogen bond,
might explain the strong antiaromatase properties of compound
3.
These results, supported by extensive experimental validation,
represent a clear improvement over previous ligand-based virtual
screening approaches for new aromatase inhibitors,21 providing
an effective new tool for the identification of novel molecular
entities acting on important cytochrome P450 targets. Common
to all members of this large superfamily is a heme cofactor that
should be carefully addressed when designing new pharma-
cophore models for such targets in order to achieve strong
binding affinities. On the other hand, fine-tuning of the ligand
potency and selectivity among different P450 targets can be
addressed, exploring specific hydrophobic, hydrogen bonding,
and shape complementarity interactions. Therefore, starting with
potent inhibitors of different cytochrome P450 enzymes such
as CYP17 and aldosterone synthase, this methodology can be
easily applied to the design of new drugs for other relevant
diseases.
The pharmacophore model built includes a broad range of
nitrogen-containing heterocycles comprising imidazole, triazole,
and pyridine, the most extensively used fragments to design
potent non-steroid aromatase inhibitors. However, it might be
extended to include other heterocycles such as rings containing
both nitrogen and sulfur or oxygen heteroatoms (thiazole,
oxazole).
In summary, we have developed and validated a new ligand-
based strategy for virtual screening of non-steroid aromatase
inhibitors. Besides the strong antiaromatase compounds identi-
fied on the NCI database, it should be possible to screen other
large compound libraries and find new potent molecules.
Experimental Section
Materials and General Methods. The NCI selected compounds
were obtained from the Drug Synthesis and Chemistry Branch,
Developmental Therapeutics Program, Division of Cancer Treat-
ment and Diagnosis of the National Cancer Institute. Letrozole was
purchased from USP (Rockville, MD). NADPH was purchased from
Sigma-Aldrich (St. Louis, MO). The [1-3H]androstenedione
(specific activity of 25.3 Ci/mmol) and the liquid scintillation
cocktail Optiphase Hisafe 2 were purchased from PerkinElmer
(Boston, MA), and the radioactive samples were counted on a
Packard Tri-Carb 2900 TR liquid scintillation analyzer.
Pharmacophore Modeling. The common-features model for
non-steroid aromatase inhibitors was performed using the Catalyst
software.23 Potent aromatase inhibitors were collected from the
literature and submitted to a conformational search with internal
energy minimization. A maximum of 250 conformers were saved
within an energy window of 20 kcal/mol above the global minimum,
using the best quality generation type. Four of these molecules
(anastrozole, letrozole, S-vorozole, and S-fadrozole)6 were included
in the training set and used to build pharmacophore hypotheses
using the HipHop22 algorithm of Catalyst. The remaining
molecules17,26-31 were included in the test set. The most active
enantiomers of vorozole52 and letrozole41 were preferred. For the
initial hypothesis generation methodology, hydrophobic and hy-
drogen bond acceptor functions were used. The “Principal” value
was set to 2 for letrozole (all features in the molecule were
considered to build the pharmacophore model) and 1 for the other
compounds (at least one mapping for each generated hypothesis
was found). The “Maximum Omitted Features” value was set to 1
for all the molecules (all but one feature was forced to map), and
default settings were used for the other options.
The nitrogen-containing aromatic heterocyclic rings were built
within Catalyst, converted into pharmacophore features using the
“View Hypothesis” workbench, and combined into a new single
fragment/function feature using the “Exclude/Or” tool. A similarity
tolerance of 0.48 was used in the shape query. This value was
chosen in order to match all the molecules of the training set.
Virtual Screening. The NCI database was downloaded from the
2007 release of the ZINC library53 and converted into a multicon-
former Catalyst database. A maximum of 100 conformations were
generated for each molecule using the “FAST” conformational
analysis model of the catDB utility program. Each pharmacophore
hypothesis was screened using the “fast flexible database search”
settings.
Postprocessing Filtering. Instant JChem34 was used for man-
agement, search, and prediction of molecular descriptors for the
NCI hits. A Lipinski rule of five33 filter was applied (not more
than 5 hydrogen bond donors, not more than 10 hydrogen bond
acceptors, molecular weight under 500 g/mol, and calculated
partition coefficient clogP of less than 5), as well as a filter based
on the maximum number of rotatable bonds (not more than 7)
and the maximum polar surface area (less than 150). Substructure
searches were performed using the same software.
Human Placental Microsomes Isolation. Human term placental
microsomes were obtained by differential centrifugation according
to the method described by Ryan38 and were used as a source of
aromatase. The microsomes were resuspended in a buffer containing
0.1 M sodium phosphate, 0.25 M sucrose, 20% glycerol, and 0.5
mM dithiothreitol, pH 7.4, and stored in aliquots at -80 °C until
needed.
Concentration-Response Study. Aromatase activity was evalu-
ated as previously described by Siiteri and Thompson.37 Briefly,
enzymatic assays were performed at 37 °C in medium containing
67 mM sodium phosphate buffer, pH 7.5, [1-3H]androstenedione
(6.6 × 105 dpm), and 270 µM NADPH in a final volume of 500
µL. The inhibitors in the study were dissolved in DMSO. The
amount of DMSO in the assay was always 2%. The reaction was
started with the addition of 30 µg of microsomal protein and stopped
after 20 min by adding 1 mL of chloroform and vortexing at 9000
rpm for 40 s. The tritiated water formed when the enzyme converts
the tritiated substrate [1-3H]androstenedione to estrone was
quantified by liquid scintillation counting. Appropriate controls
without inhibitor were performed in order to determine the
maximum enzymatic activity, to which the relative percentage of
inhibition was determined. All the molecules in the study were
initially tested at 1 µM, followed by a full concentration-response
experiment with at least eight concentrations ranging from 0.3162
nM to 160 µM. The assays were performed three times, each one
in duplicate, and the results were treated by nonlinear regression
analysis using a sigmoidal concentration-response curve with
variable slope.
Kinetic Analysis. For the kinetic study, conditions similar to
those of the concentration-response experiment were used. The
concentration of [1-3H]androstenedione was varied from 7.5 to
100 nM, three different concentrations of each inhibitor were tested,
and the reaction time was 5 min. An assay without inhibitor was
also performed. The assay was performed three times, each one in
duplicate, and the data were fitted by nonlinear regression to the
Michaelis-Menten equation. The kinetic constants, Vmax, Km, and
Ki were estimated from nonlinear regression, and the type of
inhibition was determined from Lineweaver-Burk plots.
Docking Calculations. The GOLD software40 was used to
perform flexible docking of the best compounds into the binding
cavity of a homology model of the aromatase.12 The binding site
was defined as a 10 Å sphere centered approximately 5 Å above
the heme iron and including all active site residues important to
148 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 1 NeVes et al.
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the binding. An octahedral coordinating geometry was assigned to
the heme iron, and the GOLDScore fitness function was used with
metal parameters optimized for P450 enzymes, taking account of
different H-bond acceptor types.54 Since it has been reported that
in some cases the GOLD program fails to reproduce the known
binding mode of non-steroid aromatase inhibitors, i.e., binding
through coordination between the heme iron and an acceptor
nitrogen from an aromatic heterocycle,15 substructure constraints
were created for the pyridine and imidazole rings in order place
the nitrogen within a distance between 1.9 and 2.5 Å from the heme
iron. These upper and lower values were chosen on the basis of
the analysis of PDB entries of cytochrome P450 enzymes com-
plexed with imidazole and pyridine derivatives.42-44 Twenty
independent docking runs were performed with the default genetic
algorithm search parameters. For comparison, unrestrained docking
was also performed, being able to identify docking modes in which
the nitrogen-containing heterocycle interacted correctly with the
heme iron but, however, for most molecules, failing to score these
poses in the top ranked solutions. As a consequence, the docking
algorithm spent most of the computational time exploring unrealistic
conformations.
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